Literature DB >> 7171414

Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis.

J P Haberer, P Schoeffler, E Couderc, P Duvaldestin.   

Abstract

Fentanyl kinetics were studied in patients with cirrhosis and in patients with normal hepatic and renal function undergoing surgery under general anaesthesia, the latter group served as the controls. Plasma fentanyl concentrations declined bi-exponentially in the controls with an average elimination half-life (T1/2 beta) of 263 min; total plasma clearance (Cl) as 10.8 ml min-1 kg-1, and total apparent volume of distribution (V beta) 3.81 litre kg-1. No significant change was observed in patients with cirrhosis: T1/2 beta was 304 min, Cl 11.3 ml min-1 kg-1 and V beta 4.41 litre kg-1. These data suggest that the elimination half-life of fentanyl is not primarily influenced by the rate at which it is metabolized in the liver.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7171414     DOI: 10.1093/bja/54.12.1267

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  30 in total

Review 1.  Implications of opioid analgesia for medically complicated patients.

Authors:  Howard Smith; Patricia Bruckenthal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

Review 2.  Pain management in the cirrhotic patient: the clinical challenge.

Authors:  Natasha Chandok; Kymberly D S Watt
Journal:  Mayo Clin Proc       Date:  2010-03-31       Impact factor: 7.616

Review 3.  Bioequivalence criteria for transdermal fentanyl generics: do these need a relook?

Authors:  Carmen Walter; Lisa Felden; Jörn Lötsch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 4.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 5.  Opioid metabolism.

Authors:  Howard S Smith
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

Review 6.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

7.  2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2015-05-13       Impact factor: 3.500

8.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

Review 9.  [Opioids during anesthesia in liver and renal failure].

Authors:  C Höhne; B Donaubauer; U Kaisers
Journal:  Anaesthesist       Date:  2004-03       Impact factor: 1.041

Review 10.  Role of supportive care for terminal stage hepatocellular carcinoma.

Authors:  Manoj Kumar; Dipanjan Panda
Journal:  J Clin Exp Hepatol       Date:  2014-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.